Reply to "Usefulness of Plasma Amyloid as Prescreener of the Earliest Alzheimer Pathological Changes Depends on the Study Population"

Affiliations

¹ Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.
² Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.

Comment

Inge M W Verberk et al. Ann Neurol. 2020 Jan.

. 2020 Jan;87(1):155.

doi: 10.1002/ana.25633. Epub 2019 Nov 14.

¹ Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.
² Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.

No abstract available

Comment on

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes.
Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM, Scheltens P, Teunissen CE, van der Flier WM. Verberk IMW, et al. Ann Neurol. 2018 Nov;84(5):648-658. doi: 10.1002/ana.25334. Epub 2018 Oct 4. Ann Neurol. 2018. PMID: 30196548 Free PMC article.
Usefulness of Plasma Amyloid as a Prescreener for the Earliest Alzheimer Pathological Changes Depends on the Study Population.
Prins S, Zhuparris A, Groeneveld GJ. Prins S, et al. Ann Neurol. 2020 Jan;87(1):154-155. doi: 10.1002/ana.25634. Epub 2019 Nov 13. Ann Neurol. 2020. PMID: 31675127 No abstract available.

1. Verberk IMW, Slot RE, Verfaillie SCJ, et al. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol 2018;84:648-658.
1. Vergallo A, Mégret L, Lista S, et al. Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. Alzheimers Dement 2019;15:764-775.
1. Palmqvist S, Janelidze S, Stomrud E, et al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related β-amyloid status. JAMA Neurol 2019;76:1060-1069.
1. Chatterjee P, Elmi M, Goozee K, et al. Ultrasensitive detection of plasma amyloid-β as a biomarker for cognitively normal elderly individuals at risk of Alzheimer's disease. J Alzheimers Dis 2019;71:775-783.